Influx Healthtech Ltd
Incorporated in 2020, Influx Healthtech Ltd is a CDMO which deals in nutraceuticals, Ready-to-Drink (RTD) beverages, functional nutrition and pet care.[1]
- Market Cap ₹ 649 Cr.
- Current Price ₹ 280
- High / Low ₹ 315 / 183
- Stock P/E 30.7
- Book Value ₹ 48.7
- Dividend Yield 0.00 %
- ROCE %
- ROE 19.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 5.75 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of Nifty SME Emerge
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 147 | |
| Sales growth | |
| 117 | |
| Operating Profit | 30 |
| OPM % | 20% |
| 1 | |
| Interest | 0 |
| Depreciation | 4 |
| Profit before tax | 27 |
| Tax % | 25% |
| 21 | |
| EPS in Rs | 8.87 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 42% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 19% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | Sep 2026 | |
|---|---|---|
| Equity Capital | 23 | 23 |
| Reserves | 78 | 90 |
| 0 | 0 | |
| 23 | 28 | |
| Total Liabilities | 124 | 141 |
| 28 | 34 | |
| CWIP | 3 | 15 |
| Investments | 2 | 6 |
| 90 | 86 | |
| Total Assets | 124 | 141 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2026 | |
|---|---|
| 4 | |
| -25 | |
| 45 | |
| Net Cash Flow | 23 |
| Free Cash Flow | -21 |
| CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit | 41% |
Ratios
Consolidated / View Standalone
| Mar 2026 | |
|---|---|
| Debtor Days | 84 |
| Inventory Days | 98 |
| Days Payable | 118 |
| Cash Conversion Cycle | 64 |
| Working Capital Days | 78 |
| ROCE % |
Insights
In beta| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Capacity Utilization - Nutraceuticals % |
|
|||
| Installed Capacity - Cosmetics & Ayurvedic kg per day |
||||
| Installed Capacity - Nutraceuticals kg per day |
||||
| Installed Capacity - Pet Supplements & Homecare kg per day |
||||
| Number of Clients count |
||||
| Number of Products (SKUs) count |
||||
| Top 10 Client Revenue Concentration % |
||||
| Number of Export Countries count |
||||
| Number of Manufacturing Units count |
||||
Extracted by Screener AI
Documents
Announcements
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Influx Healthtech released H1 FY27 earnings call transcript, citing 27.9% revenue growth and new facility commissioning by December-January.
-
Analysts/Institutional Investor Meet/Con. Call Updates
- Audio recording of investor conference call on November 5, 2026 shared; transcript to follow.
-
Investor Presentation
- Influx Healthtech shared H1 FY27 presentation: revenue ₹85.4 crore, EBITDA ₹18.3 crore, PAT ₹12 crore.
-
General Updates
- Board approved H1 FY2027 results on Nov. 4, 2026; NSE fine of Rs1.82 lakh paid.
-
General Updates
- Influx Healthtech Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Concalls
-
Nov 2026Transcript PPT REC
-
May 2026Transcript PPT REC
-
Nov 2025Transcript PPT REC
-
Aug 2025PPT
Business Overview:[1]
a) IHTL is a contract development and manufacturing organization (CDMO) specializing in nutraceuticals, cosmetics, pet care, and home care
b) The company has approx. 3,400+ products across dietary & nutritional supplements, cosmetics, ayurvedic/herbal formulations, veterinary feed supplements, and homecare solutions
c) It operates a comprehensive business model; provides end-to-end services,
spanning product development, manufacturing, and regulatory support, enabling clients to focus on core areas like formulation, discovery, and commercialization